1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  05/26 11:35:23 am EDT
103.60 EUR   -0.12%
05:48aSanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Lead Europe Oncology, Sanofi
AQ
05/25SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis - Form 6-K
PU
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
102.3(c) 103.7(c) 103.62(c) 103.72(c) 103.6(c) Last
2 409 766 1 670 660 1 851 699 1 667 343 1 361 866 Volume
+2.24% +1.37% -0.08% +0.10% -0.12% Change
More quotes
Estimated financial data (e)
Sales 2022 41 710 M 44 744 M 44 744 M
Net income 2022 7 983 M 8 564 M 8 564 M
Net Debt 2022 6 544 M 7 020 M 7 020 M
P/E ratio 2022 16,2x
Yield 2022 3,41%
Sales 2023 43 238 M 46 383 M 46 383 M
Net income 2023 8 166 M 8 760 M 8 760 M
Net Debt 2023 984 M 1 056 M 1 056 M
P/E ratio 2023 15,8x
Yield 2023 3,52%
Capitalization 129 B 139 B 139 B
EV / Sales 2022 3,26x
EV / Sales 2023 3,01x
Nbr of Employees 95 442
Free-Float 88,3%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (71.5%): prescription drugs in the areas of general medicine (52.7% of net sales; mainly for the treatment of diabetes and cardiovascular diseases) and specialty medicine (47.3%; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune... 
Sector
Pharmaceuticals
Calendar
06/03Presentation
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SANOFI
05:48aSanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Le..
AQ
05/25SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children age..
PU
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
05/23Fitch Raises Sanofi's Outlook To Positive From Stable on Transition Plan, Profitability
MT
05/22France's Sanofi Wins US FDA Nod for Eosinophilic Esophagitis Drug
MT
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
GL
05/20PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
AQ
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
05/20FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
DJ
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20Sanofi's Xenpozyme Secures Positive Opinion From the European Medicines Agency's CHMP
MT
05/18TRANSCRIPT : Sanofi - Special Call
CI
05/17Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV
CI
05/17ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres..
AQ
More news
News in other languages on SANOFI
05/24Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mardi 24 mai 2022
05/24GENOWAY : A suivre aujourd'hui
05/23Les valeurs à suivre demain à la Bourse de Paris - Mardi 24 mai 2022
05/23GENOWAY : propose la nomination d'Olivier Charmeil (Sanofi) au poste d'administrateur
05/23CAC40 : entame de semaine hésitante, les taux remontent
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 05/02
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 103,60 €
Average target price 115,21 €
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI17.09%138 292
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530